Wolverine Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Wolverine Asset Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-12,989	Closed	-$16K	–	1896
2017 Q4	$16K	Buy	12,989 +2,315	+22%	+$3.77K	﹤0.01%	1348
2017 Q3	$22K	Buy	10,674 +7,874	+281%	+$19.2K	﹤0.01%	1247
2017 Q2	$8K	Hold	2,800	–	–	﹤0.01%	1227
2017 Q1	$9K	Buy	+2,800	New	+$11.1K	﹤0.01%	1133
2015 Q2	–	Sell	-210	Closed	-$12.6K	–	2194
2015 Q1	$16K	Sell	210 -700	-77%	-$43.4K	﹤0.01%	1482
2014 Q4	$55K	Sell	910 -7,030	-89%	-$353K	﹤0.01%	1378
2014 Q3	$338K	Buy	+7,940	New	+$426K	0.01%	844
2013 Q4	–	Sell	-2,650	Closed	-$149K	–	3196
2013 Q3	$162K	Hold	2,650	–	–	﹤0.01%	1262
2013 Q2	$154K	Buy	+2,650	New	+$163K	﹤0.01%	1235

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Wolverine Asset Management's OREX Position: Q1 2018 in Review

Wolverine Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2018, closing a stake of 12,989 shares — an estimated $16K sold.

Wolverine Asset Management first reported a position in OREX in Q2 2013 and held it in 9 quarters. The position peaked at $338K in Q3 2014. 27 funds tracked by Wall St. Rank hold OREX as of Q1 2018.

Wolverine Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Wolverine Asset Management sold 12,989 Orexigen Therapeutics, Inc. shares in Q1 2018, an estimated $16K.
Wolverine Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 9 quarters.
Wolverine Asset Management's Orexigen Therapeutics, Inc. position peaked at $338K in Q3 2014.
27 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2018.

Based on Wolverine Asset Management's 13F filing for Q1 2018, filed 15 May 2018.